Limits...
Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI: A meta-analysis.

Luo S, Li S, Li X, Qin L, Jin S - Exp Ther Med (2014)

Bottom Line: The meta-analysis revealed that females who received transdermal testosterone treatment prior to their IVF/ICSI cycle had a two-fold increase in live birth rate [risk ratio (RR)=2.01, 95% confidence interval (CI) 1.03-3.91], clinical pregnancy rate (RR=2.09, 95% CI 1.14-3.81) and a significantly more oocyte retrieved [mean difference (MD)=1.36, 95% CI 0.82-1.90].However, the results should be interpreted with caution due to the small sample size of the studies used and the heterogeneities.Further good quality RCTs would be needed to reach further conclusions.

View Article: PubMed Central - PubMed

Affiliation: Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.

ABSTRACT
In order to identify and describe the effectiveness of transdermal testosterone pretreatment on poor ovarian responders, MEDLINE, EMBASE, the Cochrane library and the Chinese biomedical database were searched for randomized controlled trials (RCTs). Three RCTs, which compared the outcomes of female pretreatment with transdermal testosterone prior to in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) with those of control groups, were included in the present review. The three RCTs enrolled a total of 221 randomized subjects. The meta-analysis revealed that females who received transdermal testosterone treatment prior to their IVF/ICSI cycle had a two-fold increase in live birth rate [risk ratio (RR)=2.01, 95% confidence interval (CI) 1.03-3.91], clinical pregnancy rate (RR=2.09, 95% CI 1.14-3.81) and a significantly more oocyte retrieved [mean difference (MD)=1.36, 95% CI 0.82-1.90]. The current findings provide evidence that pretreatment with transdermal testosterone may improve the clinical outcomes for poor ovarian responders undergoing IVF/ICSI. However, the results should be interpreted with caution due to the small sample size of the studies used and the heterogeneities. Further good quality RCTs would be needed to reach further conclusions.

No MeSH data available.


Flow chart of study selection. IVF/ICSI, in vitro fertilization/intracytoplasmic sperm injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4061182&req=5

f1-etm-08-01-0187: Flow chart of study selection. IVF/ICSI, in vitro fertilization/intracytoplasmic sperm injection.

Mentions: The combined searches identified 116 studies for review. The titles and abstracts of the citations were cross-checked and duplicates were removed by the investigators independently. Studies were removed at initial screening based on the title or abstract if it could be determined that the publication did not meet the inclusion criteria. Ten manuscripts were selected during the initial screening. By examination of the full text, seven studies were excluded: one was a prospective self-controlled study (13), one was a duplicate study (14,15), three were clinical reviews (16–18), one was a case report (19) and one included females not undergoing IVF/ICSI (20). The flow chart for selection of the studies included is given in Fig. 1.


Effect of pretreatment with transdermal testosterone on poor ovarian responders undergoing IVF/ICSI: A meta-analysis.

Luo S, Li S, Li X, Qin L, Jin S - Exp Ther Med (2014)

Flow chart of study selection. IVF/ICSI, in vitro fertilization/intracytoplasmic sperm injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4061182&req=5

f1-etm-08-01-0187: Flow chart of study selection. IVF/ICSI, in vitro fertilization/intracytoplasmic sperm injection.
Mentions: The combined searches identified 116 studies for review. The titles and abstracts of the citations were cross-checked and duplicates were removed by the investigators independently. Studies were removed at initial screening based on the title or abstract if it could be determined that the publication did not meet the inclusion criteria. Ten manuscripts were selected during the initial screening. By examination of the full text, seven studies were excluded: one was a prospective self-controlled study (13), one was a duplicate study (14,15), three were clinical reviews (16–18), one was a case report (19) and one included females not undergoing IVF/ICSI (20). The flow chart for selection of the studies included is given in Fig. 1.

Bottom Line: The meta-analysis revealed that females who received transdermal testosterone treatment prior to their IVF/ICSI cycle had a two-fold increase in live birth rate [risk ratio (RR)=2.01, 95% confidence interval (CI) 1.03-3.91], clinical pregnancy rate (RR=2.09, 95% CI 1.14-3.81) and a significantly more oocyte retrieved [mean difference (MD)=1.36, 95% CI 0.82-1.90].However, the results should be interpreted with caution due to the small sample size of the studies used and the heterogeneities.Further good quality RCTs would be needed to reach further conclusions.

View Article: PubMed Central - PubMed

Affiliation: Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.

ABSTRACT
In order to identify and describe the effectiveness of transdermal testosterone pretreatment on poor ovarian responders, MEDLINE, EMBASE, the Cochrane library and the Chinese biomedical database were searched for randomized controlled trials (RCTs). Three RCTs, which compared the outcomes of female pretreatment with transdermal testosterone prior to in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) with those of control groups, were included in the present review. The three RCTs enrolled a total of 221 randomized subjects. The meta-analysis revealed that females who received transdermal testosterone treatment prior to their IVF/ICSI cycle had a two-fold increase in live birth rate [risk ratio (RR)=2.01, 95% confidence interval (CI) 1.03-3.91], clinical pregnancy rate (RR=2.09, 95% CI 1.14-3.81) and a significantly more oocyte retrieved [mean difference (MD)=1.36, 95% CI 0.82-1.90]. The current findings provide evidence that pretreatment with transdermal testosterone may improve the clinical outcomes for poor ovarian responders undergoing IVF/ICSI. However, the results should be interpreted with caution due to the small sample size of the studies used and the heterogeneities. Further good quality RCTs would be needed to reach further conclusions.

No MeSH data available.